Impact of dupilumab prescribing on utilization of medical and surgical therapies for chronic rhinosinusitis with nasal polyps

Christopher M Low; Allan R Wang; Michael Yong; Jayakar Nayak; Zara Patel; Peter H Hwang

doi:10.1002/alr.23325

Impact of dupilumab prescribing on utilization of medical and surgical therapies for chronic rhinosinusitis with nasal polyps

Int Forum Allergy Rhinol. 2024 Jan 31. doi: 10.1002/alr.23325. Online ahead of print.

Authors

Christopher M Low^{1

2}, Allan R Wang^{1

3}, Michael Yong¹, Jayakar Nayak¹, Zara Patel¹, Peter H Hwang¹

Affiliations

¹ Division of Rhinology-Sinus and Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, USA.
² Ear, Nose and Throat Center, Park Ridge, Illinois, USA.
³ Department of Head and Neck Surgery, University of California Los Angeles, Los Angeles, California, USA.

PMID: 38297486
DOI: 10.1002/alr.23325

Abstract

Increased dupilumab utilization coincided with decreased ESS in patients with CRSwNP between 2019 and 2021. One potential confounder was the concurrent COVID-19 pandemic, which may have negatively impacted surgery utilization rates.

Keywords: FESS; chronic rhinosinusitis; endoscopic sinus surgery; eosinophilic rhinitis and nasal polyposis; medical therapy of chronic rhinosinusitis; therapeutics.

Grants and funding

UL1 TR001085/TR/NCATS NIH HHS/United States